Technion Researchers Develop Implant That Mimics Pancreas to Regulate Diabetes in Real Time

The device operates by detecting glucose instantly, producing insulin internally and dispensing precise amounts at the exact moment required.

By Shula Rosen

A research team at the Technion–Israel Institute of Technology has developed an implant that functions like a living pancreas, automatically sensing glucose levels and releasing insulin without the need for injections, pumps, or patient action, according to a peer-reviewed study published in Science.

Led by Assistant Professor Shady Farah from the Technion’s Faculty of Chemical Engineering, and conducted in collaboration with researchers from MIT, Harvard, Johns Hopkins University, and the University of Massachusetts, the study presents what scientists describe as a self-regulating biological implant capable of continuously managing blood sugar inside the body.

The device operates by detecting glucose in real time, producing insulin internally and dispensing precise amounts at the exact moment required.

Researchers described it as an internal organ that manufactures and administers its own therapeutic response without external assistance.

One of the longstanding barriers to such technologies has been immune rejection, as the body often identifies implants as foreign and attacks them.

To address this, the team developed a protective system made of engineered therapeutic crystals that form a shield around the implant. This crystalline barrier prevents immune detection and allows the artificial pancreas to operate consistently for years.

The concept was first proposed by Farah in 2018 and has since advanced through ongoing research at his Technion laboratory alongside American academic partners, including Boston Children’s Hospital and the Johns Hopkins University School of Medicine.

Although the initial focus is diabetes, the researchers said the platform could be adapted for other chronic illnesses that require ongoing biological treatment. They stated that the implantable system may be modified to deliver therapies for conditions such as hemophilia and various metabolic or genetic disorders.

The technology has been tested successfully in mice and non-human primates. While human trials have not yet begun, the researchers characterized the results as a major step toward clinical application in patients.